Cell Therapy CDMOs with Clean FDA Inspection History
Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.
The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 31 NAI (no action), 35 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (46), Denmark (23), Germany (19), Ireland (17), UNITED KINGDOM (15).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
BMS
|
87.0 | 97.2 | 8 insp · 2 GMP | 2026-04-28 · NAI | — | 585 programs |
| 2 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 3 |
COH
|
84.0 | 97.3 | 3 insp · 0 GMP | 2025-08-20 · VAI | — | 213 programs |
| 4 |
TK
|
83.4 | 100.0 | 4 insp · 20 GMP | 2026-04-10 · NAI | — | 100 programs |
| 5 |
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.1 | 99.2 | 3 insp · 4 GMP | 2025-11-25 · NAI | Limited | — |
| 6 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 7 |
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
|
81.9 | 98.8 | 2 insp · 2 GMP | 2025-04-28 · VAI | — | 22 programs |
| 8 |
SC
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | None on file | — | — |
| 9 |
EF
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 7 insp · 0 GMP | 2026-05-15 · NAI | — | — |
| 10 |
CF
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 11 |
SG
|
80.3 | 100.0 | 3 insp · 0 GMP | 2025-02-20 · NAI | — | — |
| 12 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 13 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 14 |
RC
|
79.3 | 96.8 | 1 insp · 1 GMP | 2025-01-21 · VAI | Available | — |
| 15 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 16 |
CE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 17 |
XP
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 18 |
GP
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 19 |
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
|
77.3 | 92.9 | 2 insp · 0 GMP | 2025-03-14 · NAI | — | 34 programs |
| 20 |
SY
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 8 GMP | 2025-01-31 · NAI | — | — |
| 21 |
CY
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 22 |
CN
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 23 |
HH
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 24 |
BC
|
75.7 | 93.1 | 7 insp · 2 GMP | 2025-09-03 · VAI | — | — |
| 25 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 26 |
MB
|
73.0 | 100.0 | 0 insp · 2 GMP | None on file | — | 8 programs |
| 27 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |